» Articles » PMID: 24083250

The Roles of Hyaluronan/RHAMM/CD44 and Their Respective Interactions Along the Insidious Pathways of Fibrosarcoma Progression

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2013 Oct 2
PMID 24083250
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrosarcomas are rare malignant mesenchymal tumors originating from fibroblasts. Importantly, fibrosarcoma cells were shown to have a high content and turnover of extracellular matrix (ECM) components including hyaluronan (HA), proteoglycans, collagens, fibronectin, and laminin. ECMs are complicated structures that surround and support cells within tissues. During cancer progression, significant changes can be observed in the structural and mechanical properties of the ECM components. Importantly, hyaluronan deposition is usually higher in malignant tumors as compared to benign tissues, predicting tumor progression in some tumor types. Furthermore, activated stromal cells are able to produce tissue structure rich in hyaluronan in order to promote tumor growth. Key biological roles of HA result from its interactions with its specific CD44 and RHAMM (receptor for HA-mediated motility) cell-surface receptors. HA-receptor downstream signaling pathways regulate in turn cellular processes implicated in tumorigenesis. Growth factors, including PDGF-BB, TGFβ2, and FGF-2, enhanced hyaluronan deposition to ECM and modulated HA-receptor expression in fibrosarcoma cells. Indeed, FGF-2 through upregulation of specific HAS isoforms and hyaluronan synthesis regulated secretion and net hyaluronan deposition to the fibrosarcoma pericellular matrix modulating these cells' migration capability. In this paper we discuss the involvement of hyaluronan/RHAMM/CD44 mediated signaling in the insidious pathways of fibrosarcoma progression.

Citing Articles

Elevated RHAMM as a biomarker for predicting diabetic kidney disease in patients with type 2 diabetes.

Qi B, Lou Y, Zhu Y, Chen Y, Yang S, Meng F Clin Kidney J. 2024; 17(7):sfae196.

PMID: 39050866 PMC: 11267228. DOI: 10.1093/ckj/sfae196.


Etiology of Delayed Inflammatory Reaction Induced by Hyaluronic Acid Filler.

Lee W, Shah-Desai S, Rho N, Cho J Arch Plast Surg. 2024; 51(1):20-26.

PMID: 38425859 PMC: 10901605. DOI: 10.1055/a-2184-6554.


Selective adhesion inhibition and hyaluronan envelope reduction of dermal tumor cells by cold plasma-activated medium.

Golz A, Bergemann C, Hildebrandt F, Emmert S, Nebe B, Rebl H Cell Adh Migr. 2023; 17(1):1-19.

PMID: 37743639 PMC: 10521339. DOI: 10.1080/19336918.2023.2260642.


RHAMM/hyaluronan inhibit β-catenin degradation, enhance downstream signaling, and facilitate fibrosarcoma cell growth.

Berdiaki A, Thrapsanioti L, Giatagana E, Karamanos N, Savani R, N Tzanakakis G Mol Biol Rep. 2023; 50(11):8937-8947.

PMID: 37710072 DOI: 10.1007/s11033-023-08763-0.


Making Sense of Late Tissue Nodules Associated With Hyaluronic Acid Injections.

Goodman G, McDonald C, Lim A, Porter C, Deva A, Magnusson M Aesthet Surg J. 2023; 43(6):NP438-NP448.

PMID: 36759325 PMC: 10184938. DOI: 10.1093/asj/sjad028.


References
1.
Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

2.
Bourguignon L, Wong G, Earle C, Krueger K, Spevak C . Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010; 285(47):36721-35. PMC: 2978601. DOI: 10.1074/jbc.M110.162305. View

3.
Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L, Kovalszky I . Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol. 2002; 12(3):173-86. DOI: 10.1016/S1044-579X(02)00021-4. View

4.
Knezevich S, Garnett M, Pysher T, Beckwith J, Grundy P, Sorensen P . ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998; 58(22):5046-8. View

5.
Tolg C, Poon R, Fodde R, Turley E, Alman B . Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene. 2003; 22(44):6873-82. DOI: 10.1038/sj.onc.1206811. View